866-997-4948(US-Canada Toll Free)

Neurodegenerative Disorders Drug Development Pipeline Review, 2017

Published By :

GBI Research

Published Date : Mar 2017

Category :

Pharmaceutical

No. of Pages : 797 Pages

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

There are over 1,400 products in active development in the neurodegenerative disorders therapy area. The current market landscape consists of a number of biologics and small molecules, while the pipeline also consists of gene therapies and cell therapies, demonstrating broader pharmaceutical research and development.

Small molecule drugs dominate the pipeline, with approximately 64% of total pipeline molecules. In comparison, the number of biologics in the pipeline is much lower, representing approximately 26% of the pipeline. Overall the neurodegenerative disorders pipeline is large, with a substantial proportion of products being early-stage assets at the Preclinical development stage.

The report provides comprehensive information on the pipeline development landscape for is Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis and Multiple sclerosis, from Discovery through to the Pre-registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

  • Which companies are the most active within the pipeline for neurodegenerative disorders?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 25
Introduction 27
Neurodegenerative Disorders Report Coverage 27
Alzheimer's Disease Overview 27
Amyotrophic Lateral Sclerosis Overview 27
Huntington Disease Overview 27
Multiple Sclerosis Overview 27
Parkinson's Disease Overview 27
Therapeutics Development 28
Alzheimer's Disease 28
Amyotrophic Lateral Sclerosis 30
Huntington Disease 32
Multiple Sclerosis 34
Parkinson's Disease 36
Therapeutics under Development by Companies 38
Alzheimer's Disease 38
Amyotrophic Lateral Sclerosis 50
Huntington Disease 55
Multiple Sclerosis 58
Parkinson's Disease 68
Therapeutics under Investigation by Universities/Institutes 75
Alzheimer's Disease 75
Amyotrophic Lateral Sclerosis 78
Huntington Disease 79
Multiple Sclerosis 81
Parkinson's Disease 83
Pipeline Products Glance 85
Alzheimer's Disease 85
Amyotrophic Lateral Sclerosis 88
Huntington Disease 91
Multiple Sclerosis 94
Parkinson's Disease 97
Products under Development by Companies 101
Alzheimer's Disease 101
Amyotrophic Lateral Sclerosis 116
Huntington Disease 120
Multiple Sclerosis 123
Parkinson's Disease 134
Products under Investigation by Universities/Institutes 144
Alzheimer's Disease 144
Amyotrophic Lateral Sclerosis 150
Huntington Disease 152
Multiple Sclerosis 153
Parkinson's Disease 155
Companies Involved in Therapeutics Development 158
Alzheimer's Disease 158
Amyotrophic Lateral Sclerosis 273
Huntington Disease 318
Multiple Sclerosis 346
Parkinson's Disease 439
Therapeutics Assessment 531
Alzheimer's Disease 531
Amyotrophic Lateral Sclerosis 585
Huntington Disease 607
Multiple Sclerosis 617
Parkinson's Disease 656
Dormant Projects 684
Alzheimer's Disease 684
Amyotrophic Lateral Sclerosis 698
Huntington Disease 702
Multiple Sclerosis 705
Parkinson's Disease 714
Discontinued Products 723
Alzheimer's Disease 723
Amyotrophic Lateral Sclerosis 726
Huntington Disease 726
Multiple Sclerosis 727
Parkinson's Disease 728
Product Development Milestones 730
Alzheimer's Disease 730
Amyotrophic Lateral Sclerosis 741
Huntington Disease 752
Multiple Sclerosis 761
Parkinson's Disease 782

Appendix 796
Methodology 796
Coverage 796
Secondary Research 796
Primary Research 796
Expert Panel Validation 796
Contact Us 797
Disclaimer 797

List of Table

Number of Products under Development for Alzheimer's Disease 28
Number of Products under Development for Alzheimer's Disease – Comparative Analysis 29
Number of Products under Development for Amyotrophic Lateral Sclerosis 30
Number of Products under Development for Amyotrophic Lateral Sclerosis – Comparative Analysis 31
Number of Products under Development for Huntington Disease 32
Number of Products under Development for Huntington Disease – Comparative Analysis 33
Number of Products under Development for Multiple Sclerosis 34
Number of Products under Development for Multiple Sclerosis – Comparative Analysis 35
Number of Products under Development for Parkinson's Disease 36
Number of Products under Development for Parkinson's Disease – Comparative Analysis 37
Number of Products under Development by Companies, Alzheimer's Disease 39
Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis 51
Number of Products under Development by Companies, Huntington Disease 55
Number of Products under Development by Companies, Multiple Sclerosis 59
Number of Products under Development by Companies, Parkinson's Disease 68
Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease 75
Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 78
Number of Products under Investigation by Universities/Institutes, Huntington Disease 80
Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis 81
Number of Products under Investigation by Universities/Institutes, Parkinson's Disease 83
Comparative Analysis by Late Stage Development, Alzheimer's Disease 85
Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86
Comparative Analysis by Early Stage Development, Alzheimer's Disease 87
Comparative Analysis by Unknown Stage Development, Alzheimer's Disease 88
Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis 88
Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis 89
Comparative Analysis by Early Stage Development, Amyotrophic Lateral Sclerosis 90
Comparative Analysis by Unknown Stage Development, Amyotrophic Lateral Sclerosis 91
Comparative Analysis by Late Stage Development, Huntington Disease 91
Comparative Analysis by Clinical Stage Development, Huntington Disease 92
Comparative Analysis by Early Stage Development, Huntington Disease 93
Comparative Analysis by Late Stage Development, Multiple Sclerosis 94
Comparative Analysis by Clinical Stage Development, Multiple Sclerosis 95
Comparative Analysis by Early Stage Development, Multiple Sclerosis 96
Comparative Analysis by Unknown Stage Development, Multiple Sclerosis 96
Comparative Analysis by Late Stage Development, Parkinson's Disease 97
Comparative Analysis by Clinical Stage Development, Parkinson's Disease 98
Comparative Analysis by Early Stage Development, Parkinson's Disease 99
Comparative Analysis by Unknown Stage Development, Parkinson's Disease 100
Products under Development by Companies, Alzheimer's Disease 101
Products under Development by Companies, Amyotrophic Lateral Sclerosis 116
Products under Development by Companies, Huntington Disease 120
Products under Development by Companies, Multiple Sclerosis 123
Products under Development by Companies, Parkinson's Disease 134
Products under Investigation by Universities/Institutes, Alzheimer's Disease 144
Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 150
Products under Investigation by Universities/Institutes, Huntington Disease 152
Products under Investigation by Universities/Institutes, Multiple Sclerosis 153
Products under Investigation by Universities/Institutes, Parkinson's Disease 155
Alzheimer's Disease – Pipeline by AB Science SA, 158
Alzheimer's Disease – Pipeline by AbbVie Inc, 159
Alzheimer's Disease – Pipeline by AC Immune SA, 159
Alzheimer's Disease – Pipeline by Accera, Inc., 160
Alzheimer's Disease – Pipeline by Acelot, Inc., 160
Alzheimer's Disease – Pipeline by Actinogen Limited, 161
Alzheimer's Disease – Pipeline by Acumen Pharmaceuticals, Inc., 161
Alzheimer's Disease – Pipeline by Addex Therapeutics Ltd, 162
Alzheimer's Disease – Pipeline by Affibody AB, 162
Alzheimer's Disease – Pipeline by AFFiRiS AG, 163
Alzheimer's Disease – Pipeline by Alector LLC, 163
Alzheimer's Disease – Pipeline by Alkermes Plc, 164
Alzheimer's Disease – Pipeline by Allergan Plc, 164
Alzheimer's Disease – Pipeline by Allinky Biopharma, 165
Alzheimer's Disease – Pipeline by ALSP, Inc., 165
Alzheimer's Disease – Pipeline by Alzhyme Pty Ltd, 166
Alzheimer's Disease – Pipeline by Alzinova AB, 166
Alzheimer's Disease – Pipeline by AlzProtect SAS, 167
Alzheimer's Disease – Pipeline by Amarantus Bioscience Holdings, Inc., 167
Alzheimer's Disease – Pipeline by Amgen Inc., 168
Alzheimer's Disease – Pipeline by Anavex Life Sciences Corp., 169
Alzheimer's Disease – Pipeline by Aphios Corporation, 169
Alzheimer's Disease – Pipeline by Apodemus AB, 170
Alzheimer's Disease – Pipeline by Applied Research using OMIC Sciences, S.L., 170
Alzheimer's Disease – Pipeline by Araclon Biotech, S.L., 171
Alzheimer's Disease – Pipeline by Archer Pharmaceuticals, Inc., 171
Alzheimer's Disease – Pipeline by ArmaGen Inc., 172
Alzheimer's Disease – Pipeline by Artery Therapeutics, Inc., 172
Alzheimer's Disease – Pipeline by AskAt Inc., 172
Alzheimer's Disease – Pipeline by Astellas Pharma Inc., 173
Alzheimer's Disease – Pipeline by AstraZeneca Plc, 174
Alzheimer's Disease – Pipeline by Asubio Pharma Co., Ltd., 175
Alzheimer's Disease – Pipeline by Ausio Pharmaceuticals, LLC, 175
Alzheimer's Disease – Pipeline by Avineuro Pharmaceuticals, Inc., 176
Alzheimer's Disease – Pipeline by Axon Neuroscience SE, 176
Alzheimer's Disease – Pipeline by Axovant Sciences Ltd., 177
Alzheimer's Disease – Pipeline by Axsome Therapeutics, Inc., 177
Alzheimer's Disease – Pipeline by Axxam SpA, 177
Alzheimer's Disease – Pipeline by Beactica AB, 178
Alzheimer's Disease – Pipeline by Berg LLC, 178
Alzheimer's Disease – Pipeline by BioArctic Neuroscience AB, 179
Alzheimer's Disease – Pipeline by Bioasis Technologies Inc., 179
Alzheimer's Disease – Pipeline by Biogen Inc, 180
Alzheimer's Disease – Pipeline by Biomar Microbial Technologies, 180
Alzheimer's Disease – Pipeline by Bionature E.A. Ltd., 181
Alzheimer's Disease – Pipeline by Boehringer Ingelheim GmbH, 181
Alzheimer's Disease – Pipeline by Bristol-Myers Squibb Company, 182
Alzheimer's Disease – Pipeline by Bsim2, 182
Alzheimer's Disease – Pipeline by Cardax Pharmaceuticals, Inc., 183
Alzheimer's Disease – Pipeline by Carna Biosciences, Inc., 183
Alzheimer's Disease – Pipeline by Celon Pharma Sp. z o.o., 184
Alzheimer's Disease – Pipeline by CHA Bio & Diostech Co., Ltd., 184
Alzheimer's Disease – Pipeline by Chase Pharmaceuticals Corporation, 185
Alzheimer's Disease – Pipeline by Clera Inc., 185
Alzheimer's Disease – Pipeline by Cognition Therapeutics, Inc., 186
Alzheimer's Disease – Pipeline by Cognosci, Inc., 186
Alzheimer's Disease – Pipeline by CohBar, Inc., 187
Alzheimer's Disease – Pipeline by Connexios Life Sciences Pvt. Ltd., 187
Alzheimer's Disease – Pipeline by ContraVir Pharmaceuticals, Inc., 188
Alzheimer's Disease – Pipeline by Corium International, Inc., 188
Alzheimer's Disease – Pipeline by Coronis Partners Ltd., 189
Alzheimer's Disease – Pipeline by Cortice Biosciences, Inc., 189
Alzheimer's Disease – Pipeline by Critical Outcome Technologies Inc., 189
Alzheimer's Disease – Pipeline by Crossbeta Biosciences B.V., 190
Alzheimer's Disease – Pipeline by D-Pharm Ltd., 190
Alzheimer's Disease – Pipeline by Daewoong Pharmaceutical Co., Ltd., 191
Alzheimer's Disease – Pipeline by Daiichi Sankyo Company, Limited, 191
Alzheimer's Disease – Pipeline by Daval International Limited, 192
Alzheimer's Disease – Pipeline by DermaXon, LLC, 192
Alzheimer's Disease – Pipeline by Dongkook Pharmaceutical Co., Ltd., 193
Alzheimer's Disease – Pipeline by Eisai Co., Ltd., 193
Alzheimer's Disease – Pipeline by Eli Lilly and Company, 194
Alzheimer's Disease – Pipeline by Emergent BioSolutions Inc., 195
Alzheimer's Disease – Pipeline by EncephRx, Inc., 195
Alzheimer's Disease – Pipeline by Endece, LLC, 196
Alzheimer's Disease – Pipeline by ENKAM Pharmaceuticals A/S, 196
Alzheimer's Disease – Pipeline by Ensemble Therapeutics Corporation, 197
Alzheimer's Disease – Pipeline by Ensol Biosciences Inc., 197
Alzheimer's Disease – Pipeline by Epigen Biosciences, Inc., 198
Alzheimer's Disease – Pipeline by Euroscreen S.A., 198
Alzheimer's Disease – Pipeline by Evotec AG, 199
Alzheimer's Disease – Pipeline by F. Hoffmann-La Roche Ltd., 199
Alzheimer's Disease – Pipeline by FORUM Pharmaceuticals Inc., 200
Alzheimer's Disease – Pipeline by Genentech, Inc., 200
Alzheimer's Disease – Pipeline by Genervon Biopharmaceuticals, LLC, 201
Alzheimer's Disease – Pipeline by GlaxoSmithKline Plc, 201
Alzheimer's Disease – Pipeline by GliaCure Inc., 202
Alzheimer's Disease – Pipeline by Glialogix, Inc., 202
Alzheimer's Disease – Pipeline by Golden Biotechnology Corp., 203
Alzheimer's Disease – Pipeline by Grifols, S.A., 203
Alzheimer's Disease – Pipeline by H. Lundbeck A/S, 204
Alzheimer's Disease – Pipeline by Heptares Therapeutics Limited, 204
Alzheimer's Disease – Pipeline by HitGen LTD, 205
Alzheimer's Disease – Pipeline by Humanetics Corporation, 205
Alzheimer's Disease – Pipeline by Ichor Medical Systems, Inc., 206
Alzheimer's Disease – Pipeline by Icure Pharmaceutical Inc., 206
Alzheimer's Disease – Pipeline by Immungenetics AG, 207
Alzheimer's Disease – Pipeline by Impel NeuroPharma, Inc., 207
Alzheimer's Disease – Pipeline by ImStar Therapeutics Inc., 208
Alzheimer's Disease – Pipeline by Inovio Pharmaceuticals, Inc., 208
Alzheimer's Disease – Pipeline by IntelGenx Corp., 209
Alzheimer's Disease – Pipeline by Intellect Neurosciences, Inc., 209
Alzheimer's Disease – Pipeline by Intra-Cellular Therapies, Inc., 210
Alzheimer's Disease – Pipeline by INVENT Pharmaceuticals, Inc., 210
Alzheimer's Disease – Pipeline by Io Therapeutics, Inc., 211
Alzheimer's Disease – Pipeline by Iproteos S.L., 211
Alzheimer's Disease – Pipeline by Jeil Pharmaceutical Co., Ltd., 212
Alzheimer's Disease – Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., 212
Alzheimer's Disease – Pipeline by Johnson & Johnson, 213
Alzheimer's Disease – Pipeline by K-Stemcell Co., Ltd., 213
Alzheimer's Disease – Pipeline by Kadmon Corporation, LLC, 214
Alzheimer's Disease – Pipeline by Kalgene Pharmaceuticals Inc., 214
Alzheimer's Disease – Pipeline by Kareus Therapeutics, SA, 215
Alzheimer's Disease – Pipeline by KineMed, Inc., 215
Alzheimer's Disease – Pipeline by Krenitsky Pharmaceuticals Inc., 216
Alzheimer's Disease – Pipeline by Kyowa Hakko Kirin Co., Ltd., 216
Alzheimer's Disease – Pipeline by Lead Discovery Center GmbH, 217
Alzheimer's Disease – Pipeline by Les Laboratoires Servier SAS, 217
Alzheimer's Disease – Pipeline by Lipopharma Therapeutics SL, 218
Alzheimer's Disease – Pipeline by Living Cell Technologies Limited, 218
Alzheimer's Disease – Pipeline by Lupin Limited, 219
Alzheimer's Disease – Pipeline by M3 Biotechnology, Inc., 219
Alzheimer's Disease – Pipeline by ManRos Therapeutics, 220
Alzheimer's Disease – Pipeline by MedDay SA, 220
Alzheimer's Disease – Pipeline by Medestea Research & Production S.p.A., 221
Alzheimer's Disease – Pipeline by MedImmune, LLC, 221
Alzheimer's Disease – Pipeline by Medisyn Technologies, Inc., 222
Alzheimer's Disease – Pipeline by MEDRx Co., Ltd., 222
Alzheimer's Disease – Pipeline by Merck & Co., Inc., 223
Alzheimer's Disease – Pipeline by Metabolic Solutions Development Company, LLC, 223

List of Chart

Number of Products under Development for Alzheimer's Disease 28
Number of Products under Development for Alzheimer's Disease – Comparative Analysis 29
Number of Products under Development for Amyotrophic Lateral Sclerosis 30
Number of Products under Development for Amyotrophic Lateral Sclerosis – Comparative Analysis 31
Number of Products under Development for Huntington Disease 32
Number of Products under Development for Huntington Disease – Comparative Analysis 33
Number of Products under Development for Multiple Sclerosis 34
Number of Products under Development for Multiple Sclerosis – Comparative Analysis 35
Number of Products under Development for Parkinson's Disease 36
Number of Products under Development for Parkinson's Disease – Comparative Analysis 37
Number of Products under Development by Companies, Alzheimer's Disease 38
Number of Products under Development by Companies, Amyotrophic Lateral Sclerosis 50
Number of Products under Development by Companies, Huntington Disease 55
Number of Products under Development by Companies, Multiple Sclerosis 58
Number of Products under Development by Companies, Parkinson's Disease 68
Number of Products under Investigation by Universities/Institutes, Alzheimer's Disease 75
Number of Products under Investigation by Universities/Institutes, Amyotrophic Lateral Sclerosis 78
Number of Products under Investigation by Universities/Institutes, Huntington Disease 79
Number of Products under Investigation by Universities/Institutes, Multiple Sclerosis 81
Number of Products under Investigation by Universities/Institutes, Parkinson's Disease 83
Comparative Analysis by Late Stage Development, Alzheimer's Disease 85
Comparative Analysis by Clinical Stage Development, Alzheimer's Disease 86
Comparative Analysis by Early Stage Products, Alzheimer's Disease 87
Comparative Analysis by Late Stage Development, Amyotrophic Lateral Sclerosis 88
Comparative Analysis by Clinical Stage Development, Amyotrophic Lateral Sclerosis 89
Comparative Analysis by Early Stage Products, Amyotrophic Lateral Sclerosis 90
Comparative Analysis by Late Stage Development, Huntington Disease 91
Comparative Analysis by Clinical Stage Development, Huntington Disease 92
Comparative Analysis by Early Stage Products, Huntington Disease 93
Comparative Analysis by Late Stage Development, Multiple Sclerosis 94
Comparative Analysis by Clinical Stage Development, Multiple Sclerosis 95
Comparative Analysis by Early Stage Products, Multiple Sclerosis 96
Comparative Analysis by Late Stage Development, Parkinson's Disease 97
Comparative Analysis by Clinical Stage Development, Parkinson's Disease 98
Comparative Analysis by Early Stage Products, Parkinson's Disease 99
Comparative Analysis by Unknown Stage Development, Parkinson's Disease 100
Assessment by Monotherapy Products, Alzheimer's Disease 531
Assessment by Combination Products, Alzheimer's Disease 532
Number of Products by Top 10 Targets, Alzheimer's Disease 533
Number of Products by Stage and Top 10 Targets, Alzheimer's Disease 533
Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease 556
Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease 556
Number of Products by Top 10 Routes of Administration, Alzheimer's Disease 581
Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease 581
Number of Products by Top 10 Molecule Types, Alzheimer's Disease 583
Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease 583
Assessment by Monotherapy Products, Amyotrophic Lateral Sclerosis 585
Assessment by Combination Products, Amyotrophic Lateral Sclerosis 586
Number of Products by Top 10 Targets, Amyotrophic Lateral Sclerosis 587
Number of Products by Stage and Top 10 Targets, Amyotrophic Lateral Sclerosis 587
Number of Products by Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis 595
Number of Products by Stage and Top 10 Mechanism of Actions, Amyotrophic Lateral Sclerosis 595
Number of Products by Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis 603
Number of Products by Stage and Top 10 Routes of Administration, Amyotrophic Lateral Sclerosis 603
Number of Products by Top 10 Molecule Types, Amyotrophic Lateral Sclerosis 605
Number of Products by Stage and Top 10 Molecule Types, Amyotrophic Lateral Sclerosis 605
Assessment by Monotherapy Products, Huntington Disease 607
Number of Products by Top 10 Targets, Huntington Disease 608
Number of Products by Stage and Top 10 Targets, Huntington Disease 608
Number of Products by Top 10 Mechanism of Actions, Huntington Disease 611
Number of Products by Stage and Top 10 Mechanism of Actions, Huntington Disease 611
Number of Products by Top 10 Routes of Administration, Huntington Disease 614
Number of Products by Stage and Top 10 Routes of Administration, Huntington Disease 614
Number of Products by Top 10 Molecule Types, Huntington Disease 616
Number of Products by Stage and Top 10 Molecule Types, Huntington Disease 616
Assessment by Monotherapy Products, Multiple Sclerosis 617
Number of Products by Top 10 Targets, Multiple Sclerosis 619
Number of Products by Stage and Top 10 Targets, Multiple Sclerosis 619
Number of Products by Top 10 Mechanism of Actions, Multiple Sclerosis 634
Number of Products by Stage and Top 10 Mechanism of Actions, Multiple Sclerosis 634
Number of Products by Top 10 Routes of Administration, Multiple Sclerosis 652
Number of Products by Stage and Top 10 Routes of Administration, Multiple Sclerosis 652
Number of Products by Top 10 Molecule Types, Multiple Sclerosis 654
Number of Products by Stage and Top 10 Molecule Types, Multiple Sclerosis 654
Assessment by Monotherapy Products, Parkinson's Disease 656
Assessment by Combination Products, Parkinson's Disease 657
Number of Products by Top 10 Targets, Parkinson's Disease 658
Number of Products by Stage and Top 10 Targets, Parkinson's Disease 658
Number of Products by Top 10 Mechanism of Actions, Parkinson's Disease 668
Number of Products by Stage and Top 10 Mechanism of Actions, Parkinson's Disease 668
Number of Products by Top 10 Routes of Administration, Parkinson's Disease 680
Number of Products by Stage and Top 10 Routes of Administration, Parkinson's Disease 680
Number of Products by Top 10 Molecule Types, Parkinson's Disease 682
Number of Products by Stage and Top 10 Molecule Types, Parkinson's Disease 682

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *